NeoGenomics is trading at $16.88, up +4.20%, with the cause of the intraday rise unclear.
- No clear company-specific announcement or catalyst for the October 13 move was found.
- The latest company news surfaced was the October 5 leadership succession and preliminary Q3 revenue update; analyst upgrades were prior context, not evidence of a new catalyst.
- Broader markets were nearly flat, while healthcare-sector context was negative; neither clearly explains the gain.